Food effect and biocomparison of two formulations of the dual orexin receptor antagonist almorexant in healthy male subjects.
Hoch
Matthias
M
Actelion Pharmaceuticals Ltd, Department of Clinical Pharmacology, Allschwil, Switzerland. matthias.hoch@actelion.com
Hoever
Petra
P
Haschke
Manuel
M
Krähenbühl
Stephan
S
Dingemanse
Jasper
J
D000081:Acetamides / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D000328:Adult; D001682:Biological Availability; D002214:Capsules; D018592:Cross-Over Studies; D018565:Food-Drug Interactions; D006207:Half-Life; D006801:Humans; D006993:Hypnotics and Sedatives / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D007546:Isoquinolines / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D008297:Male; D064446:Orexin Receptors; D011930:Reaction Time / Q000187:drug effects; D043562:Receptors, G-Protein-Coupled / Q000037:antagonists & inhibitors*; D018013:Receptors, Neuropeptide / Q000037:antagonists & inhibitors*; D013607:Tablets; D013647:Task Performance and Analysis; D013810:Therapeutic Equivalency; D014851:Wakefulness / Q000187:drug effects; D055815:Young Adult
D000081:Acetamides; D002214:Capsules; D006993:Hypnotics and Sedatives; D007546:Isoquinolines; D064446:Orexin Receptors; D043562:Receptors, G-Protein-Coupled; D018013:Receptors, Neuropeptide; D013607:Tablets; C519150:almorexant